<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01273675</url>
  </required_header>
  <id_info>
    <org_study_id>201008056R</org_study_id>
    <nct_id>NCT01273675</nct_id>
  </id_info>
  <brief_title>An Investigation on the Effect of Candesartan on Early Diabetic Nephropathy</brief_title>
  <official_title>An Investigation on the Effect of Candesartan on Early Diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is well understood that hypertension, dyslipidemia, and diabetes mellitus are the major&#xD;
      risks of chronic kidney disease. Current guidelines recommend screening kidney estimated&#xD;
      glomerular filtration function with serum creatinine. But it is not the utmost effective&#xD;
      method and the GFR would be underestimated. Since good correlation was noticed between serum&#xD;
      creatinine and chronic kidney disease, urinary microalbumin levels is better for patients&#xD;
      with risks of chronic kidney diseases. With adequate and early education, or antihypertensive&#xD;
      agents with angiotensin converting enzyme inhibitors (ACEi) or angiotensin II receptor&#xD;
      blockers (ARB), all could alleviate renal function deterioration and the severity of&#xD;
      proteinuria. As a result, high sensitive methods is urgent and needed for early screening and&#xD;
      diseases following up under medication with ACEi and ARB in chronic kidney disease patients.&#xD;
      In this project, the investigators are going to include the patients with typy II diabetes&#xD;
      mellitus combining with hypertension who are treated with antihypertensive agents. Such&#xD;
      volunteers will be treated with Candesartan 8-16mg/ day and maintain systolic blood pressure&#xD;
      &lt;130 mm/Hg, diastolic blood pressure &lt; 80 mm/ Hg as the goal. Therefore, this project would&#xD;
      make effort on correlation with urinary microalbumin and other biomarkers changes under&#xD;
      Candesartan treatment- one of ARB medication for 12 weeks, and further exploration of new&#xD;
      biomarkers that may be related to renal parenchymal injuries.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2010</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and Urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Type II Diabetic diasese with hypertension ( systolic 140-160 mm/Hg, dystolic 80-100 mm/Hg)&#xD;
        for 8 weeks.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Type II Diabetic disease with hypertension (BP: systolic 140-160 mm/Hg, diastolic&#xD;
             80-100 mm/Hg) for 8 weeks.&#xD;
&#xD;
          2. HbA1c&lt; 8.0%&#xD;
&#xD;
          3. Cre. &lt;1.5 g/dL and eGFR: 89 - 30 mL/min/1.73 m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy&#xD;
&#xD;
          2. During the observation, BP: systolic &gt;160 mm/Hg, diastolic &gt;100 mm/Hg).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu Chu-Su, PhD candidate</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>January 6, 2011</study_first_submitted>
  <study_first_submitted_qc>January 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2011</study_first_posted>
  <last_update_submitted>January 7, 2011</last_update_submitted>
  <last_update_submitted_qc>January 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Chu-Su, Yu</name_title>
    <organization>National Taiwan University Hospital</organization>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Primary disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

